A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
Clinical trial NCT05324501 · TERMINATED
Trial details
- NCT number
- NCT05324501
- Sponsor
- Biodexa Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-19
- Primary completion
- 2024-09-10
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.